Tag: advanced

Radiation can be safely omitted in selected patients with locally advanced rectal cancer

24news0021

By the staff of ASCO Post Posted: 6/4/2023 11:46:00 AM Last update: 6/4/2023 10:53:02 Locally advanced rectal cancer patients with chemotherapy-responsive tumors can safely forego radiation therapy before surgery, based on results from the PROSPECT trial. These data were presented by Deborah Schrag, MD, FASCO, MPHat the ASCO Annual Meeting 2023 (Abstract LBA2) and contextually published in The New England Journal of Medicine(effectiveness data) and theJournal of Clinical Oncology (data on patient-reported outcomes). Omitting radiotherapy can reduce short- and long-term side effects that affect quality of life, providing similar results…

Read More

Nivolumab with AVD Provides PFS Benefit Compared to Brentuximab Vedotin Plus AVD in Advanced Hodgkin Lymphoma

24news0021

Treatment with nivolumab (Opdivo) combined with doxorubicin, vinblastine, and dacarbazine (AVD) resulted in prolonged progression-free survival (PFS) compared with brentuximab vedotin (Adcetris) plus AVD in patients with advanced-stage classic Hodgkin lymphoma (cHL ), according to the results of the Phase 3SWOG S1826 study (NCT03907488) presented at the 2023 ASCO Annual Meeting. At a median follow-up of 12.1 months, results showed that patients who received nivolumab plus AVD (n = 489) experienced an estimated 1-year PFS rate of 94% (95% CI, 91% -96%) versus 86% (95% CI, 82%-90%) among patients treated…

Read More